Current and future antiplatelet therapies: emphasis on preserving haemostasis

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hematology

Background:

• Antiplatelet drugs like aspirin and P2Y12 antagonists are crucial for treating arterial thrombosis and acute coronary syndromes.
• Current antiplatelet therapies, while effective, increase bleeding risk, limiting their potency and leading to adverse outcomes.
• A therapeutic ceiling exists for conventional antiplatelet drugs due to the trade-off between efficacy and bleeding.

Purpose of the Study:

• To review the limitations of current antiplatelet drugs.
• To explore novel antiplatelet therapies that differentiate between thrombosis and hemostasis.
• To discuss the development of safer antiplatelet agents.

Main Methods:

• Review of preclinical studies and in vivo experimental data.
• Analysis of novel antiplatelet targets and mechanisms.
• Discussion of therapeutic strategies for arterial thrombosis.

Main Results:

• Preclinical studies identified novel antiplatelet agents with the potential to inhibit thrombosis while maintaining hemostasis.
• These novel agents target pathways including PI3Kβ, protein disulfide-isomerase, and platelet GPVI-mediated adhesion.
• Understanding the differences between hemostasis and thrombosis is key to developing safer drugs.

Conclusions:

• A therapeutic ceiling has been reached with existing antiplatelet drugs due to increased bleeding risk with higher potency.
• Novel antiplatelet therapies targeting specific pathways offer a promising avenue for safer and more effective treatment of arterial thrombosis.
• Future research focuses on developing agents that selectively inhibit thrombosis without compromising hemostasis.